Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Summit Corporation PLC (SUMM)

  Print      Mail a friend

Wednesday 24 February, 2010

Summit Corporation PLC

Trading Statement

Summit Corporation plc
("Summit" or "the Company")


Oxford, UK, 24 February 2010, Summit (AIM: SUMM), a leading UK drug discovery
company with a portfolio of partnered drug programmes and a proprietary
iminosugar technology platform, announces a pre-close trading update ahead of
its final results for the year ended 31 January 2010.  Summit anticipates
announcing its final results in early May 2010.

The Board are pleased with the recent progress of the Company in spite of the
challenging economic climate. The Company is now focussed on developing its
iminosugar platform having disposed of non-core businesses and having made
significant reductions in its cash burn. These changes enabled the Company to
successfully complete a fund-raise in December 2009 and the Board now looks
forward with confidence to reaching a number of key milestones from existing
partnered programmes and the signing of new platform or programme based deals.

Strong Financial Position
In December 2009, Summit raised £5.4 million through a Placing and Open Offer to
current and new investors which, excluding milestone payments from existing and
potential future deals will provide the business with cash resources until at
least December 2011.  This investment ensures the Company is funded well beyond
the point where it anticipates receiving significant milestone payments from our
partners and will accelerate the development of Summit's innovative iminosugar
technology platform.

Summit had a cash position of £6.0 million on 31 January 2010.

£2.2 million Wellcome Trust Grant
In addition in December 2009, Summit was awarded a grant worth up to £2.2
million from the Wellcome Trust to fund the development of the Company's C.
difficile infectious disease programme.  C. difficile is a life threatening
pathogen for which current therapy options are limited.  In 2008 in the UK, C.
difficile was responsible for over three times more deaths than the MRSA
superbug.  Summit has identified a novel class of compounds that are effective
against C. difficile and the grant will completely fund their development until
2012 at which time the Company would expect to have a compound ready to enter
human clinical trials.  The Company drew down the first instalment of the grant
of £550,000 in January 2010.

The C. difficile programme has significant commercial potential and the Company
will seek to capitalise on this as the programme advances.  Furthermore, the
Wellcome Trust funding endorses the scientific innovation and expertise that
exists within Summit.

DMD Programme Enters Clinical Trials
The Company received a further boost in January 2010, whenBioMarin
Pharmaceuticals Inc. announced that it had initiated a Phase 1 clinical study of
SMT C1100 (also known as BMN 195).  Discovered by Summit scientists, SMT C1100
is a small molecule utrophin upregulator for the treatment of Duchenne muscular
dystrophy (DMD), a fatal genetic disease for which there is currently no cure.
 The programme was licensed to BioMarin in July 2008 and Summit is eligible to
receive significant development and regulatory milestone payments and tiered
royalties rising to a low-teen percentage over this potentially disease
modifying medicine.  BioMarin has indicated that initial top-line results from
this Phase I trial are expected in Q3 2010.

New medicines from Iminosugars
Summit's major R&D focus is on developing new medicines from its proprietary
iminosugar drug discovery technology platform.   This technology platform is
attracting increasing levels of interest and Summit is exploring potential
collaborations with a number of pharmaceutical and biotechnology companies to
investigate its platform in a range of major therapy areas.  The Board believes
the next 12 months will be an important period in the development of this
innovative technology.

Internally, Summit is currently focusing its research activities in the
multi-billion dollar therapeutic areas of diabetes and infectious diseases.
 This includes SMT 14224, which is being developed as a new treatment for type
II diabetes with data on this compound indicating that it potentially works via
a new mechanism of action.  Initial marketing of SMT 14224 has resulted in
interest being shown from several leading pharmaceutical companies and Summit is
investing a portion of the new finance into studies designed to add further
value to this programme.

Dr Steven Lee, PhD, Chief Executive Officer of Summit commented:
"I am pleased that Summit has emerged from a challenging year as a leaner and
more focussed business.  Following the pleasing level of support received from
current and new investors, I believe the business is now well positioned to
deliver shareholder value from our set of novel and increasingly valuable

                                    - END -

For more information, please contact:


 Steven Lee, PhD

 Richard Pye, PhD                        Tel: +44 (0)1235 443 951

 Singer   Capital   Markets   (Nominated

 Shaun Dobson / Claes Spång              Tel: +44 (0)20 3205 7500

 Peckwater PR

 Tarquin Edwards                         Tel: +44 (0)7879 458 364
                                         [email protected]
                                         <mailto:[email protected]

About Summit

Summit is a leading UK based drug discovery company with a portfolio of
partnered drug programmes and a major focus on developing new therapeutics from
its proprietary iminosugar drug discovery platform.

Summit believes iminosugars are the key to gaining access to several disease
mechanisms where classical drug candidates have had little success, and
therefore offer a major opportunity for the discovery and development of new

Carbohydrates play critical roles in maintaining correct function of many normal
processes in healthy individuals and provide a wealth of new targets for drug
discovery.  Iminosugars have the capability of accessing such targets and offer
the potential of generating new medicines in a variety of major therapy areas.
Summit is currently focussed on metabolic diseases, including diabetes, and
infectious diseases.

Summit has a commercial track record of signing programme agreements and
currently has a product portfolio comprising of a number of drug programmes with
partners including BioMarin Pharmaceuticals, Orient Pharma, Evolva, the Wellcome
Trust and the Lilly TB Drug Discovery Initiative.  This portfolio requires no
further investment from Summit but in the future may generate success based
milestone payments of over $160 million and sales royalties rising to a low teen
percentage for the Company.

The company listed on the alternative investment market (AIM) of the London
Stock Exchange in October 2004 - symbol: SUMM.  Further information about the
company is available at <>.

Forward Looking Statements
This document contains "forward-looking statements" within the meaning of the
U.S. Private Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as "anticipates", "intends", "plans",
"seeks", "believes", "estimates", "expects" and similar references to future
periods, or by the inclusion of forecasts or projections.

Forward-looking statements are based on the Company's current expectations and
assumptions regarding our business, the economy and other future conditions.
Because forward-looking statements relate to the future, by their nature, they
are subject to inherent uncertainties, risks and changes in circumstances that
are difficult to predict. The Company's actual results may differ materially
from those contemplated by the forward-looking statements. The Company cautions
you therefore that you should not rely on any of these forward-looking
statements as statements of historical fact or as guarantees or assurances of
future performance. Important factors that could cause actual results to differ
materially from those in the forward-looking statements and regional, national,
global political, economic, business, competitive, market and regulatory




a d v e r t i s e m e n t